This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Phage Display Veterinary Vaccine Development
Phages are precise adversaries of bacterial hosts, and the advent of phage display technology marked a pivotal moment in the evolution of phage-based veterinary vaccines. These vaccines leverage the capability to express multiple antigen copies on the immunogenic phage particle surface, resulting in a robust and efficient immune response. BioVenic offers phage display veterinary vaccine development services, harnessing innovative techniques and selecting suitable phage types to facilitate your research and development.
Phage Display Systems
The commonly used phage display systems for veterinary vaccine delivery are as follows, and BioVenic has established vaccine platforms for all four of these phages. You can choose the display system that best suits your needs based on your considerations, and we will provide comprehensive services to support your R&D.
| Systems | Proteins Used for Fusion Display | Copy Number | Size of Displayed Antigen |
|---|---|---|---|
| Filamentous | pVIII (major coat protein 5 kDa) | 2700 | 6-8 AA |
| pIII (minor coat protein 45 kDa) | 4-5 | Large proteins | |
| T4 | Soc (small outer capsid 9 kDa) | 810–960 | Up to 840 AA |
| Hoc (highly antigenic outer capsid 40 kDa) | 155-160 | Up to 180 AA | |
| T7 | gp 10 A | 415 | 40-50 AA |
| gp 10 B | 1 | Up to 1200 AA | |
| λ | gpD (outer capsid protein) | 420 | Up to 1000 AA |
| gpV (tail protein) | 192 |
Our Services
Phage Display Library Construction
We will use PCR (Polymerase Chain Reaction) to amplify the coding sequence of the antigen gene after you have identified the target antigen sequence of pathogens. Based on your requirements, BioVenic selects the appropriate phage display system and then employs molecular biology techniques to clone these segments into the genome of the phage responsible for encoding the coat protein.
Phage Production
BioVenic offers gene expression services by introducing the constructed phage display library into host bacteria, such as Escherichia coli. This infection prompts the host bacteria to express the fusion genes contained in the phage display library, resulting in the production of a large quantity of phage particles through bacterial cultivation. Our commitment to maintaining a safe and sterile bacterial culture environment ensures the efficient production of phage particles expressing the antigen genes.
Fig.1 Overall strategy for vaccine development using phage display. 1
Phage Screening
To enhance the effectiveness of veterinary vaccines under development, it is necessary to screen the phages that have successfully bound to the target antigen gene sequence. BioVenic offers biopanning services for your phage display vaccine development.
Fig.1 Overall strategy for vaccine development using phage display. 1
Phage Identification
BioVenic offers phage identification services, utilizing PCR technology to amplify DNA sequences within the phage, sequencing the extracted genes to obtain the sequence information of the fusion gene. Our analysis services compare the sequencing data with the sequence of the target antigen gene to determine the protein or peptide sequences that bind to the target molecule.
Why Choose Us?
- Multiple phage display systems for veterinary vaccine development.
- Complete phage library construction and display process.
- Strict phage screening and profiling.
- Vaccine Development for different animal species.
Phage display has emerged as a crucial tool in the field of biotechnology, finding applications across various domains, particularly in veterinary vaccine development for livestock, poultry, aquaculture species, companion animals. Shifting your research focus to phage display veterinary vaccines is a bold choice. Please contact BioVenic for more information for phage display veterinary vaccine development.
Reference
- Palma, Marco. "Epitopes and Mimotopes Identification Using Phage Display for Vaccine Development against Infectious Pathogens." Vaccines 11.7 (2023): 1176.